Contact

ECHO™-NK

From iPSC to IND in 18 months

Clinic-Ready NK cells · €3M Fixed Cost · 20B+ Cell Supply

The solution for every
NK therapy developer.

With more than 15 years of experience in iPSCs, Cellistic has developed expertise in scaling and standardizing production processes. Echo™-NK – with its fixed-price model, 18-month turnaround time, and 20B+ cell yield – was specifically designed to address key challenges in NK cell therapy development, supporting reliable translation to clinical studies. 

iPSC-based allogeneic NK developers

If you’re advancing an iPSC-NK program, you’ll find that Echo™-NK can get you to clinic with financial predictability, reproducibility, and scalability unmatched among CDMOs.

Healthy donor–derived allogeneic NK developers

By leveraging iPSCs, you can gain lower costs per dose, eliminate donor variability through renewable iPSC-based starting material, and take advantage of regulatory-aligned GMP processes to reduce risk.

Autologous NK developers

Shift from your current resource-intensive, "one-to-one” approach to a “one-to-many” model that is sustainable for both patients and your company, all while reshaping the pharmaco-economics of your cell therapy.

Echo-Nk Solution Hero

Meeting NK development challenges head-on.

Natural Killer (NK) cell therapy developers have a unique opportunity to overcome the hurdles of autologous and donor-derived approaches — but only by simultaneously.

Drug Developer Pain points Cellistic Solution
Speed to Clinic

Long and unpredictable development timelines, 24 months+.

Standardized iPSC-to-NK workflows enable predictable, accelerated timelines. No process or analytical development is required, only 7 months for process adaptation, and the entire offering in 18 months.
Budget Predictability

Difficulty forecasting costs due to process variability.

Fixed pricing model for accurate and reliable cost forecasting.
Supply Security & Scalability

Achieving sufficient yields for long-term supply security. 

Scalable, high-yield Echo™-NK process delivering consistent, off the shelf supply.
Regulatory

Advancing with confidence in a comparatively new regulatory environment.

Your NK drug product is produced in our purpose-built EMA-certified, FDA compliant facility.

Discover what comes standard with the Echo™-NK offering.

Key elements of our Core Offering — delivering 20+ billion cells in 18 months for €3 million — include:

White CheckmarkEnd-to-end platform process — client provides their unique CAR construct(s)

White CheckmarkScalable iPSC-to-NK expansion (30×) with bioreactors up to 50–100L, from early to commercial scale

White CheckmarkUp to 200 doses per batch

White CheckmarkFeeder-free process with fully defined, GMP-compliant materials

White CheckmarkRobust, qualified vendor supply chain

Artboard 1 1
Echo-NK Core Offerings Graphic

Echo™-NK Platform Overview & In-Process Controls.

Echo-NK Platform Overview & In-Process Controls

A process built for quality and consistency in iPSC-NK manufacturing.

Generating clinical-grade iPSC NK cells at consistent yields with Echo™-NK  is made possible through a proven process built in unit operations (with multiple in-process controls) and through multiple cryopreservation steps. 

GMP Facility for iPSC-Derived allogeneic cell therapies.

In Mont-Saint-Guibert, Belgium, you’ll find our headquarters – and the world’s first facility dedicated exclusively to iPSC-based cell therapy manufacturing. It’s an agile, flexible, 20,000+ sq. ft. facility that incorporates leading-edge technologies. All materials and operations are validated according with cGMP standards, and manufacturing is conducted in an EMA-certified, FDA compliant GMP facility.

5 Grade B Manufacturing Suites

Grade B
Manufacturing Suites

4 Grade C Manufacturing Suites

Grade C
Manufacturing Suites

6 Clean Rooms for CLD/GMP Manufacturing

Clean Rooms for
CLD/GMP Manufacturing

5 Grade B Manufacturing Suites

Grade B
GTP Inspections

7 GMP Inspections

GMP Inspections

10+ Allogeneic Batches Released

Allogeneic Batches Released

Scientific Advantages

Checkmark IconPlug-and-play platform
Save time through an 80% pre-developed framework and, where needed, product-specific customization.

Checkmark IconReliable starting material
Ensure reproducibility, simplify IP management, and provide long-term supply security though renewable GMP iPSC banks and STAR-CRISPR™ editing.

Checkmark IconIn-house QC/QA
Inform release criteria and comparability protocols through assays that test for identity, safety, and purity.

Checkmark IconScalable, compliant manufacturing
Scale confidently – and in regulatory alignment –  through Pulse™ automation, 3D bioreactors, and processes that can yield up to 100L using the same technologies.

Commercial Advantages

Checkmark IconQuick time-to-value
Speed trial starts and positively impact company valuation through access to clinic-ready material in 18 months (versus industry-standard 24-month timelines).

Checkmark IconEfficient processes
Capitalize on scalable production process founded on iPSC cell lines that eliminate the need of expensive component editing at a manufacturing scale (i.e., viral vectors/DNA/RNA).

Checkmark IconOptimized cost structure and scalability
Improve margins, market penetration, and long-term program sustainability by leveraging favorable per-dose COGS, scalable production, and a broader patient reach.

Checkmark IconStrategic advantage
Enhance competitiveness, investor confidence, and program longevity by adopting a model purpose-built to meet the needs of NK cell therapy innovators.

Frequently asked questions

Group 35338-1

Learn more about what Echo™-NK can do for you.

If accelerating your NK program efficiently is a critical priority for your team, then you'll find our team at Cellistic to be an ideal partner. No matter your starting point, our expertise can help you advance to clinic with speed, scalability, and cost efficiency.